Denise Armellini, MD
Endocrinology, Diabetes & Metabolism · Fairfax, VANPI 1811107162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $121,137 of the $152,117 with a category attached, or 79.6%. Novo Nordisk accounts for 88.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $61,483 and has fallen 99.8% since, to $136 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $598.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$134K
- AstraZeneca$16K
- IBSA Pharma Inc.$177
- Lilly USA, LLC$157
- Amgen$120
- Boehringer Ingelheim$96
- plus $899 from 20 others
What the payments were for
- Consulting fees$1,8601%
- Speaking & faculty fees$121,13780%
- Travel & lodging$23,57315%
- Food & beverage$5,4924%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 147 | $134,441 |
| AstraZeneca | 36 | $16,228 |
| IBSA Pharma Inc. | 10 | $177 |
| Lilly USA, LLC | 8 | $157 |
| Amgen | 1 | $120 |
| Boehringer Ingelheim | 5 | $96 |
| Amneal Pharmaceuticals LLC | 7 | $95 |
| Exelixis Inc. | 1 | $87 |
| Sanofi-aventis U.S. LLC | 6 | $86 |
| Dexcom, Inc. | 3 | $79 |
| Shire North American Group Inc | 4 | $73 |
| AbbVie | 3 | $57 |
| Radius Health, Inc. | 3 | $54 |
| Tandem Diabetes Care, Inc. | 3 | $42 |
| Abbott | 2 | $42 |
| Johnson & Johnson | 2 | $41 |
| Insulet Corporation | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $38 |
| Sequel Med Tech, LLC | 2 | $33 |
| Pfizer | 1 | $28 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| Merck | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$152,117 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $111,243 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $44,103 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $37,587 |
| JardianceEmpagliflozin | 20 | $26,258 |
| MounjaroTirzepatide | 20 | $23,510 |
| HumalogInsulin Lispro | 17 | $7,796 |
| Novolog FlexpenInsulin Aspart | 11 | $4,676 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $3,789 |
| SynthroidLevothyroxine Sodium | 41 | $3,672 |
| Levothyroxine Sodium | 47 | $751 |
| Irbesartan | 22 | $498 |
| Rosuvastatin Calcium | 16 | $461 |
| Metformin Hcl ErMetformin Hcl | 41 | $328 |
| Liothyronine Sodium | 16 | $303 |
| Ezetimibe | 13 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $134,441 | $111,24373 claims |
| Lilly USA, LLCMounjaro, Humalog | $157 | $31,30637 claims |
| Boehringer IngelheimJardiance | $96 | $26,25820 claims |
| AbbVieSynthroid | $57 | $3,67241 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $95 | $75147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Fairfax
- Samim EnayatFairfax$217K
- Yasser OusmanFairfax$53K
- Roy LangleyFairfax$5K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.